SWD in: (i) a rat genetic model of absence sei(cid:173)
`zures (intrathalamic administration) [Z. Liu, M.
`Vergnes, A. Depaulis, C. Marescaux, Neuro(cid:173)
`science 48, 87 (1992)] and (ii) two pharmacologic
`models of absence seizures (i.p. administration)
`[O. C. Snead, Eur. J. Pharmacol. 213, 343 (1992)].
`26. G. Karlson, M. Schmutz, C. Kolb, H. Bittiger, H.-R.
`Olpe, in GABA8 Receptors in Mammalian Func(cid:173)
`tion, N. G. Bowery et al., Eds. (Wiley, Chichester,
`United Kingdom, 1990), pp. 349-365.
`27. P. C. Waldmeier, P. Wicki, J.-J. Feldtrauer, P. A.
`Baumann, Naunyn-Schmiedeberg 's Arch. Phar(cid:173)
`makol. 337, 289 (1988) ; R. A. Deisz and D. A.
`Prince,.). Physiol. (London) 412, 513 (1989) ; D. D.
`Mott and D. V. Lewi s, Science 252, 1718 (1991) .
`28. B63HF1
`from C57Bl/6JEi
`is the F1
`crossed with C3H/HESnJ males. We refer to the
`B63HF1 strain, with which lh/lh is congenic, as
`wild or +/+ . We maintain lh!lh and +/+ mouse
`colonies at the Duke University Vivarium , using
`stocks from Jackson Laboratory (Bar Harbor,
`ME) .
`29. Supported by grants from the Veterans Adminis(cid:173)
`tration (D.A.H. and WA.W.) and NIH (D.A.H .,
`W.A.W., and RAM.). We thank H. Bittiger for the
`gift of CGP 35348 [European patent 463560-A 1 (2
`January 1992); priority CH-002092 (22 June
`1990)] ; V. H. MacMillan for HPLC measurements;
`N. Lambert, D. V. Lewis, J. 0. McNamara, D. D.
`Mott, C. Shin, and H. S. Swartzwelder for critical
`reading and discussion; and B. Worrell and S.
`Sneed for administrative assistance.
`21January 1992; accepted 22 May 1992
`Nitric Oxide: A Physiologic Mediator of
`Penile Erection
`Arthur L. Burnett, Charles J. Lowenstein, David S. Bredt,
`Thomas S. K. Chang, Solomon H. Snyder*
`Nitric oxide (NO) is a cytotoxic agent of macrophages, a messenger molecule of neurons,
`and a vasodilator produced by endothelial cells. NO synthase, the synthetic enzyme for
`NO, was localized to rat penile neurons innervating the corpora cavernosa and to neuronal
`plexuses in the adventitial layer of penile arteries. Small doses of NO synthase inhibitors
`abolished electrophysiologically induced penile erections. These results establish NO as
`a physiologic mediator of erectile function.
`N itric oxide mediates bactericidal and tu(cid:173)
`moricidal actions of macrophages (1) and
`blood vessel relaxation of endothelial cells
`(2) . NO may also be a major neuronal
`messenger (3) . lmmunohistochemical stud(cid:173)
`ies localize NO synthase (NOS) to neurons
`in the brain as well as to discrete popula(cid:173)
`tions of autonomic nerves in the periphery
`(4) , where NO fulfills most characteristics
`of a neurotransmitter. For instance, NOS is
`highly localized to cell bodies and fibers of
`the myenteric plexus of the gastrointestinal
`(4). The nonadrenergic, non(cid:173)
`cholinergic relaxation evoked by physiolog(cid:173)
`ic stimulation of myenteric plexus neurons
`is potently and selectively blocked by NOS
`inhibitors (5) .
`Penile erection is thought to involve
`parasympathetic, neuronally mediated re(cid:173)
`laxation of the blood vessels as well as of
`the trabecular meshwork of smooth muscle
`that comprises the corpora cavernosa (6).
`The neuronal chemical mediator of erec(cid:173)
`tion has not been established. Vasoactive
`intestinal polypeptide (VIP) occurs in lim-
`A. L. Burnett and T. S. K. Chang, Department of
`Urology, Johns Hopkins University School of Medi(cid:173)
`cine, 725 North Wolfe Street, Baltimore, MD 21205.
`C. J. Lowenstein, Department of Cardiology, Johns
`Hopkins University School of Medicine, 725 North
`Wolfe Street, Baltimore, MD 21205.
`D. S. Bredt and S. H. Snyder, Departments of Neuro(cid:173)
`science, Pharmacology, and Molecular Sciences, and
`Psychiatry, Johns Hopkins University School of Medi(cid:173)
`cine, 725 North Wolfe Street, Baltimore, MD 21205.
`'To whom correspondence should be addressed.
`ited populations of nerve fibers in the penis
`(7), but direct administration of VIP does
`not fully mimic physiologic erection (8). In
`isolated smooth muscle from the corpus
`cavernosa of several species, relaxation
`evoked by electrical field stimulation could
`be blocked by NOS inhibitors, as reported
`in some studies (9) but not in others (10).
`Blockage of relaxation by NOS inhibitors
`can establish NO as a mediator of caver(cid:173)
`nosal muscle relaxation but does not permit
`conclusions as to whether it is a neuronal,
`transmitter-like messenger and a physiolog(cid:173)
`ic mediator of erection.
`Several portions of the genitourinary
`tract of rat displayed substantial NOS ac(cid:173)
`tivity, monitored by the conversion of
`[3H]arginine to [3H]citrulline (Table 1) _
`High concentrations in the pelvic plexus,
`referred to in the rat as the major pelvic
`ganglion, suggest a neuronal role for NOS _
`Amounts of NOS in the membranous ure(cid:173)
`thra exceeded amounts in the pelvic plexus
`and were three to four times larger than
`those in the penis and the bladder neck and
`considerably larger than those in the pros(cid:173)
`tate. This regional distribution of NOS
`activity was confirmed by protein immuno(cid:173)
`blot (1 J) _
`We conducted
`staining of rat penile tissue (Fig. I) with an
`antiserum that is highly selective for NOS
`and stains NOS specifically in a variety of
`rat peripheral tissues and in brain tissue (4).
`All immunohistochemical staining of NOS
`• VOL. 257
`• 17 JULY 1992
`in penile tissues was blocked by preabsorp(cid:173)
`tion with recombinant NOS protein ( 11) .
`The antibody to NOS stained the pelvic
`plexus and its axonal processes that form
`the cavernous nerve (Fig. IA), located
`immediately adjacent to the deep caver(cid:173)
`nosal artery, the major arterial source of the
`corpus cavernosum. In the proximal penis,
`the nerve plexus in the adventitia of the
`deep cavernosal arteries stained prominent(cid:173)
`ly as did neuronal processes in the sinusoids
`and the periphery of the corpora cavernosa
`(Fig. lB) . This staining circumscribed the
`· corpora cavernosa directly below their fi(cid:173)
`brous capsules, the tunica albuginea_ Neu(cid:173)
`ronal staining of the deep cavernosal arter(cid:173)
`ies continued as the arteries subdivided into
`the intracorporal network of helicine arter(cid:173)
`ies (Fig. ID). In the most distal portion of
`the corpora, staining diminished as the
`helicine arteries were replaced with cavern(cid:173)
`ous spaces (Fig. IE). The distal part of the
`penis superficial to the corpora cavernosa
`contained dorsal penile nerve fibers that
`stained for NOS (Fig. I, E and F)- Dorsal
`penile and cavernosal arteries stained for
`NOS both in the adventitial and endothe(cid:173)
`lial layers, although endothelial staining
`was faint in the cavernosal vessels. NOS
`staining in the urethra was associated with
`smooth muscle or the submucosal vascula(cid:173)
`ture or both (Fig. IE) and fits with the
`substantial urethral NOS catalytic activity
`(Table 1).
`The neural specificity of NOS staining
`was established by bilateral cavernous nerve
`transection, after which we no longer ob(cid:173)
`served penile neurons stained for NOS (Fig.
`IC), although endothelial staining persist(cid:173)
`ed (11). To ensure that this distribution
`was not species-specific, we conducted im(cid:173)
`munohistochemical localizations of NOS
`from the penes of dogs and demonstrated
`essentially identical localizations to nerve
`plexuses in the adventitial layers of penile
`arteries and the dorsal nerves of the dog
`The localization of NOS to neuronal
`fibers innervating blood vessels and the
`corpora cavernosa of the penis suggested a
`possible role for NO as a neuronal mediator
`of erection. We examined this possibility in
`a rat model of penile erection in which we
`electrically stimulated the cavernous nerves
`of intact rats by using optimal parameters
`that evoked physiologic erection (12) _
`L-Nitroarginine, a potent and selective in(cid:173)
`hibitor of NOS, markedly diminished pe(cid:173)
`nile erections (Table 2) . As little as I mg
`per kilogram of body weight (mg/kg) ad(cid:173)
`ministered intravenously (i. v.) significantly
`reduced erection, and 2.5 mg/kg produced
`more than a 50% reduction. At 5 mg/kg,
`nitroarginine almost completely inhibited
`erection. Intravenous bolus injections of
`1 of 3
`Lilly v. LA BioMed

`L-arginine (25 mg/kg) partially reversed the
`L-nitroarginine (2.5 mg/kg) inhibition of
`penile erection. The physiologic L-isomer
`of N-methylarginine, another selective in(cid:173)
`hibitor of NOS that is less potent than
`L-nitroarginine, significantly inhibited pe(cid:173)
`nile erection at 10 mg/kg with a larger effect
`of 40 mg/kg. By contrast the D-isomer,
`which does not inhibit NOS, also failed to
`block erection even at 40 mg/kg. Large
`doses of atropine (1 mg/kg i.v.) did not
`inhibit electrically stimulated erections.
`These results fit with recent experiments
`that show inhibitions of erection by caver(cid:173)
`nosal nerve stimulation in rabbits after in(cid:173)
`jections of L-nitroarginine directly into the
`corpus cavemosum (13). The dose required
`for maximal effect, about 2 mg, is effective(cid:173)
`ly several hundred times greater than the
`parenteral doses we administered to rats.
`Also, L-arginine failed to reverse effects of
`nitroarginine in rabbits ( 13) .
`The stereospecificity for inhibition of
`penile erection displayed by N-methylargi(cid:173)
`nine as well as the very substantial potency
`of nitroarginine indicates that the blockage
`of penile erection comes from the inhibi(cid:173)
`tion of NOS activity. This conclusion is
`supported by observations that relaxation of
`isolated corpus cavemosum muscle strips in
`vitro after electrical field stimulation is
`blocked by NOS inhibitors (9), although
`Table 1. NOS activity in the urogenital system.
`We measured the activity of NOS by monitoring
`the conversion of [3 H)arginine to 13 H)citrulline
`as described (21) on specimens obtained by
`anatomical dissection of adult male Sprague(cid:173)
`Dawley rats. Tissue was homogenized in 1 O
`volumes (w/v) 50 mM tris (pH 7.4), 1 mM EDTA,
`1 mM EGTA, and centrifuged at 10,000g for 1
`min at 4°C. Enzyme assays contained 25 µ.I of
`tissue supernatant and 50 µ.I of 100 nM
`[3H)arginine (53 Ci/mmol; 1 Ci = 37 gigabec(cid:173)
`querels), 10 mM nicotinamide adenine dinucle(cid:173)
`otide phosphate (reduced form), and 10 mM
`CaCl2 . After a 15-min incubation at room tem(cid:173)
`perature , the assays were terminated with 3 ml
`of 20 mM Hepes (pH 5.5) with 2 mM EDTA and
`applied to 0.5-ml Columns of Dowex AG50WX8
`(Na+ form) . [3 H]Citrulline was quantified by
`liquid scintillation spectroscopy of the 3-ml
`flow-through . The data are expressed as mean
`values ± SEM for five experiments and normal(cid:173)
`ized to cerebellar NOS activity assayed in par(cid:173)
`allel. According to the Duncan multiple range
`test, the amounts of NOS catalytic activity in the
`pelvic plexus and urethra are different from the
`amounts in the prostate, bladder neck, and
`penis .,
`[3 H)Citrulline
`formation [cpm min - 1
`(mg protein) - 1 ± SEM]
`Pelvic plexus
`Membranous urethra
`Bladder neck
`408 ± 36
`857 ± 105
`212 ± 44
`214 ± 31
`36 ± 15
`others report a failure of the inhibitor
`N-methylarginine to prevent such relax(cid:173)
`ation (JO). The selective localization of
`NOS in penile neurons that subserve erec(cid:173)
`tion, as well as the ability of NOS inhibi(cid:173)
`tors to block physiologic erection selective(cid:173)
`ly, potently, and completely, imply that
`NO is the major if not sole neuronal medi(cid:173)
`ator of erection. As in the myenteric plexus
`of the gastrointestinal system, NO in the
`penis appears to fulfill the principal criteria
`of a neurotransmitter. For instance, it is
`localized to the neurons that innervate the
`smooth muscle of the penis. Furthermore,
`direct application of NO or its precursors
`relaxes the muscle in a manner similar to
`the relaxation produced by nerve stimula(cid:173)
`tion (9), and the effects of neuronal stimu(cid:173)
`lation are blocked by inhibitors of the
`formation of NO.
`.. , ...
`Fig. 1. lmmunohistochemical localization of NOS in the rat penis . lmmunohistochemistry was
`performed as described (4) on slide-mounted pelvic tissue sections from adult male Sprague(cid:173)
`Dawley rats. The primary antibody was an affinity-purified NOS antiserum (1 :50 dilution), which was
`subsequently bound with the use of an avidin-biotin-peroxidase system (Vector Laboratories) with
`diaminobenzidine as a chromogen. (A) The pelvic plexus (PP) containing neural cell bodies
`adjacent to glands ot the lateral prostate (LP) . (B) Obl ique section through the crus of the corpus
`cavernosum that depicts staining primarily localized to nerves in the · adventitia of the deep
`cavernosal artery and its major tributaries (arrows) and to nerves extending into erecti le tissue (C}
`Duplicate section as (B) that was obtained in an animal 1 week after bilateral transection of the
`cavernous nerves. Faint staining can be observed in the adventitia of the major arterial divisions. (D}
`Coronal section through the pelvis at the level of the proximal penis that shows the corpora
`cavernosa merging in midline. The deep cavernosal arteries have tapered (arrows}, whereas arterial
`subdivisions, the helicine arteries, have extensively arborized . The capsule containing the erectile
`tissue, the tunica albuginea, does not stain (thick arrow) . (E) Cross section through the visible penis
`distally showing prominent nerve fiber staining of the dorsal penis and staining of the urethra
`(arrow). Bilateral cavernous spaces (CS) within the corporal bodies are shown. (F) A magnified view
`of the dorsal penis from (E) showing discrete nerve fibers (NF) . Staining is also localized to the
`adventitia (arrows) and endothelium (arrowhead) of dorsal arteries. [Scale bars in (A) to (C) , and (F}
`= 300 µ.m; bars in (D) and (E) = 1 mm].
`• VOL. 257
`• 17 JULY 1992
`2 of 3

`Table 2. Effects of NOS inhibition on penile erection in intact rats. Penile erection was induced
`electrically with a Grass S48 square wave stimulator in anesthetized (pentobarbital , 50 mg/kg,
`administered intraperitoneally) male Sprague-Dawley rats with optimal stimulation parameters ( 12) .
`Bipolar silver wire electrodes were attached unilaterally to the cavernous nerve that arises from the
`ipsilateral pelvic plexus situated dorsolateral to the prostate. lntracavernous pressures were
`measured (Gould Polygraph, Cleveland, Ohio) with a 25-gauge needle inserted unilaterally at the
`base of the penis and connected to an lsotec pressure transducer. Neurostimulation was performed
`until a 10-s maximal pressure recording was achieved, but no stimulation lasted longer than 90 s.
`At least 1 O min elapsed between repeated stimulations. Arginine derivations were administered into
`the jugular vein. Data represent mean values ± SEM as a percentage of the baseline pressure
`(range 35 to 50 mmHg) recorded 15 min after agents were administered.
`% lntracavernous
`pressure (± SEM)
`L-Nitroarginine methyl ester
`75 ± 7
`47 ± 5
`16 ± 1
`10 ± 10.3
`63 ± 3
`17 ± 2
`15 ± 5
`128 ± 5
`Acetycholine is the classical neurotrans(cid:173)
`mitter for the parasympathetic inne"CVation
`of penile nerves responsible for erection.
`However, penile erection does not appear
`to require either cholinergic or adrenergic
`mechanisms (14). VIP was advanced as a
`candidate transmitter for the mediation of
`erection on the basis of its immunohisto(cid:173)
`chemical localization in penile neurons (7).
`However, the density of VIP-containing
`penile neurons in several species (8) is
`substantially less than that of the NOS(cid:173)
`containing neurons that we have observed
`in rats and dogs. Injections of VIP into the
`dog and human penis produce some erec(cid:173)
`tion, but responses are relatively modest
`and may be elicited primarily by increased
`venous outflow resistance rather than by
`the dilation of penile arteries or by the
`relaxation of corpora cavernosa muscle (8).
`Lesion studies demonstrate that NOS-con(cid:173)
`taining fibers in the adventitia of cerebral
`arteries come from parasympathetic cell
`bodies in the sphenopalatine ganglia, many
`of which also contain VIP ( 15). In the
`myenteric plexus, NOS-containing neurons
`also contain VIP. Whereas NOS inhibitors
`can almost completely block neuronally
`mediated gastric relaxation, antibodies to
`VIP can produce up to a 30% blockage of
`this relaxation with NOS inhibitors block(cid:173)
`ing the remaining relaxation (16). Thus, in
`various portions of the parasympathetic
`nervous system, VIP and NO might func(cid:173)
`tion as cotransmitters.
`The immunohistochemical visualization
`of NOS in penile neurons clarifies function(cid:173)
`al penile innervation as described in hu(cid:173)
`mans by Walsh and Donker (17) and as
`described by others in rats (18) . NOS-
`containing cavernous nerve processes pen(cid:173)
`etrate the corpora cavernosa, appear to
`envelop the centrally situated cavernosal
`arteries, and also extend into the corporal
`bodies radially and circumferentially. This
`implies a direct neural modulation of the
`vasoactivity of penile arteries, intracorporal
`sinusoids, and the entire tubular-shaped
`corpora cavernosa. Besides well-character(cid:173)
`ized neuroregulation of arterial dilation in
`the penis, our findings suggest that penile
`erection also involves an active process of
`neurally regulated sinusoidal and corporal
`expansion rather than passive engorgement
`of cavernous spaces with blood supplied by
`the penile arteries. The immunohistochem(cid:173)
`ical localization of NOS in the urethra
`parallels its high NOS catalytic activity,
`which suggests that NO may be involved in
`the urethral functions that regulate urinary
`continence or micturition.
`The involvement of NO in erection has
`clinical implications. Priapism, a condition
`of painful, prolonged erections unassociated
`with sexual arousal or desire, occurs in sev(cid:173)
`eral clinical situations, including as many as
`40% of patients with sickle cell anemia ( 19).
`NOS inhibitors such as nitroarginine might
`have therapeutic utility in priapism. Further(cid:173)
`more, some varieties of impotence may re(cid:173)
`sult from a dysfunction in the NOS-contain(cid:173)
`ing neuronal system. Our delineation of
`NOS neuronal localizations within the cor(cid:173)
`pora cavernosa may facilitate surgical ap(cid:173)
`proaches to correct penile abnormalities and
`injuries, such as hypospadias and Peyronie's
`disease, respectively congenital and acquired
`conditions conspicuous for disabling penile
`curvature. Impotence associated with their
`operative management (20) might be avoid-
`ed with surgical techniques designed to pre(cid:173)
`serve NOS innervation.
`1. J. B. Hibbs, Z. Vavrin, R. R. Taintor, J. lmmunol.
`138, 550 (1987) : J. B. Hibbs, Jr., R. R. Taintor, Z.
`Vavrin, E. M. Rachlin, Biochem. Biophys. Res.
`Commun. 157, 87 (1988); C. F. Nathan and J.B.
`Hibbs, Jr. , Curr. Opin. Jmmunol. 3, 65 (1991).
`2. R. F. Furchgott and J. V. Zawadzki, Nature 288,
`373 (1980); S. Moncada, R. M. J. Palmer, E. A
`Higgs, Biochem. Pharmacol. 38, 1709 (1989) ; R.
`M. J. Palmer, A G. Ferrige, S. Moncada, Nature
`327, 524 (1987); R. F. Furchgott and P. M. Van(cid:173)
`houtte, FASEB J. 3, 2007 (1988); L. J. lgnarro,
`Annu. Rev. Pharmacol. Toxico/. 30, 535 (1990).
`3. D. S. Bred! and S. H. Snyder, Neuron 8, 3 (1992);
`J. Garthwaite, Trends Neurosci. 14, 60 (1991).
`4. D. S. Bredt, P. M. Hwang, S. H. Snyder, Nature
`347, 768 (1990) .
`5. K. M. Desai, W. C. Sessa, J. R. Vane, ibid. 351, 477
`(1991); T. M. Cocks and J. A Angus, Naunyn(cid:173)
`Schmiedeberg's Arch. Pharmacol. 341, 364
`(1990); A T01trup, D. Svane, A Forman, Am. J.
`Physiol. 260, G385 (1991); H. Bult et al., Nature
`345, 346 (1990); J. S. Gillespie, X. Liu, W. Martin,
`Br. J. Pharmacol. 98, 1080 (1989); M. V. Ramago(cid:173)
`pal and H. J. Leighton, Eur. J. Pharmaco/. 174, 297
`(1989); A Gibson, S. Mirzazadeh, A J. Hobbs, P.
`K. Moore, Br. J. Pharmacol. 99, 602 (1990).
`6. R. Blanco et al., Am. J. Physiol. 254, 468 (1988).
`7. J.M. Polak, S. Mina, J. Gu, S. R. Bloom, Lancet ii,
`217 (1981); E. A Willis, B. Ottesen, G. Wagner, F.
`Sundler, J. Fahrenkrug, Ute Sci. 33, 383 (1983).
`8. E. A Kiely, S. R. Bloom, G. Williams, Br. J. Ural.
`64, 191 (1989) ; J. B. Roy, R. L. Petrone, S. I. Said,
`J. Ural. 143, 302 (1990); K. P. Juenemann et al.,
`ibid. 138, 871 (1987); W. D. Steers, J. McConnell,
`G. S. Benson, ibid. 132, 1048 (1984).
`9. R. S. Pickard, P. H. Powell, M. A Zar, Br. J.
`Pharmacol. 104, 755 (1991); L. J. lgnarro et al.,
`Biochem. Biophys. Res. Commun. 170, 843
`(1990) ; N. Kim, K. M. Azadzoi, I. Goldstein, S.
`deTejada, J. Clin. Invest. 88, 112 (1991); F.
`Holmquist, H. Hedlund, K. E. Andersson, Acta
`Physiol. Scand. 141, 441 (1991); J. Rajfer, W. J.
`Aronson , P. A Bush, F. J. Dorey, L. J. lgnarro, N.
`Engl. J. Med. 326, 90 (1992).
`10. J. S. Gillespie and L. Xiaorong , Br. J. Pharmacol.
`97, 453P (1989); N. 0. Sjostrand, J. Eldh, V. E.
`Samuelson, S. Alavanta, E. Klinge, Acta Physiol.
`Scand. 140, 297 (1990).
`11 . A L. Burnett, C. J. Lowenstein, D. S. Bred!, T. S.
`K. Chang, S. H. Snyder, data not shown.
`12. D. M. Quinlan, R. J. Nelson, A W. Partin, J. L.
`Mostwin, P. C. Walsh, J. Urol. 141, 656 (1989).
`13. F. Holmquist, C. G. Stief, V. Jones, K. E. Ander(cid:173)
`son, Ac ta Physiol. Scand. 143, 299 (1991) .
`14. G. S. Benson, World J. Ural. 1, 209 (1983).
`15. K. Nozaki et al., J. Cereb. Blood Flow Metab., in
`16. C. G. Li and M. J. Rand, Eur. J. Pharmaco/. 191,
`303 (1990) .
`17. P. C. Walsh and P. J. Donker, J. Ural. 128, 492
`(1982) .
`18. W. G. Dail, D. Trujillo, D. De la Rosa, G. Walton,
`Anat. Rec. 224, 94 (1989) .
`19. A M. Emond, R. Holman, R. J. Hayes, G. R.
`Serjeant, Arch. Intern. Med. 140, 1434 (1980) .
`20. J. M. Palomer, H. Halikiopoulos, R. Thomas, J.
`Ural. 123, 680 (1980).
`21 . D.S. Bred! eta/., Nature351, 714 (1991).
`22. Supported by U.S. Public Health Service grants
`MH-18501, DA-00266, and DK-19300, contract
`DA-271-90-7408, and Research Scientist Award
`training grant DK-07552
`(A.LB.). training grant GM-07309 (D.S.B.), NIH
`Physician Scientist Award HL-02451 (C.J.L.), and
`a gift from Bristol-Myers Squibb.
`3 March 1992; accepted 28 May 1992
`• VOL 257
`• 17 JULY 1992
`3 of 3

This document is available on Docket Alarm but you must sign up to view it.

Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.

Access Government Site

We are redirecting you
to a mobile optimized page.

Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket